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Hepatocellular carcinoma (HCC) is a major l1ealth problem with more than 66o,ooo new cases per yea r world-
wide [1J . HCC is resistant to commonly used tre~tments like chemother~py and radiotherapy and new an ti-HCC 
therapies are urgently needed. Sorafenib was the first approved smal l molecule against HCC and underlines 
th e importance of identifying potential new anti-HCC drugs [2] . 
Thirty-t wo 6-substitu ted metllyl 3-aminothieno [3,2-b]pyridine-2-carboxylates, previously pre pared by some 
of us [3.4]. were evaluated as potential new anti-HCC agents by studying tlleir in vitro cell growth inhibition on 
bum an HepG2 cells, generally regarded as a good HCC model, and hepa to toxicity using a porcine liver primary 
cell culture (PLP1). The presence of amino groups linked to a benzene moiety on ll1e substituent of the 6 -posi-
tion emerged as tile key element for the anti-HCC activity. 
The methyl 3-amino-6-((3-am inophenyl)ethynyl]thieno[ 3,2-b]pyridine-2-carboxylate was llw most potent 
compound presenting HepG2 Gl;o = 1.2 pM against 2.9 pM of the positive control ellipticine, with no observed 
hepatotoxicity (PLP1 GIS0>125 pM against 3-3 pM of ellipticine). QSAR stud ies were also performed to prov ide 
mechanistic insights for the ant i-HCC activi ty and hepatotoxicity of the compounds. Tile correlat ions obtained 
using molecular and 1D descrip tors revealed th e importance o f the presence o f amino groups and other hydro-
gen bond donors for anli-HCC activi t y, and hydrogen bond acceptors for hepatotoxicity. The best cor relations 
were obtained w it h 3D descriptors belonging to d ifferent subcategories f or anti-HCC activity and hepatotoxic-
ity, respectively. These results point to d ifferent molecular mechanisms of action of the compounds for ant i-
HCC ac tivi ty and hepatotoxicity. This work presents some prom ising 6-substituted methyl 3-aminothieno[ },2-
b]pyridine-2-carboxylates for potential use in chemotllerapy against HCC Moreover these co mpounds may 
also be used as scaffolds for further synthesis of more potent and less toxic analogues. 
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